AAIC 2026

Alzheimer's Association International Conference (AAIC)

July 12-15, 2026

London, United Kingdom

‍

Meet 28bio at AAIC 2026. We will not have a booth, but will be meeting with teams focused on strengthening preclinical decision-making in Alzheimer's disease research — particularly those looking to improve how they model disease pathology, evaluate anti-amyloid beta drug efficacy, and assess overall likelihood of clinical success before advancing programs.

Our new CNS-3D Alzheimer's Model helps researchers assess whether drug candidates reduce amyloid-driven cellular, inflammatory, molecular, and functional changes. The model captures key hallmarks of Alzheimer's pathology in a human-relevant 3D system, offering a faster, more physiologically relevant alternative to traditional in vivo approaches.

‍

Poster Presentation

Sunday, July 12, 2026

Integration Of Microglia into A 3D CNS Cortical Organoid for Modeling Alzheimer’s Disease

The unmet medical need associated with Alzheimer’s disease (AD) and AD-related dementias (ADRD) is daunting. Despite tremendous public and private resources directed toward understanding AD pathology and developing drug candidates, progress has been frustratingly slow and there are few approved treatments successfully providing disease modifications. Using human induced pluripotent derived stem cells (iPSC) 28bio has developed a scalable cortical organoid model (CNS-3D) that exhibits robust, reproducible and clinically relevant functional phenotypes.

While standard CNS-3D organoids exhibit the most highly represented cell types (neurons and glia), we developed and improved the platform by integrating microglia to enable an often-absent neuroinflammatory component critical to modeling Alzheimer’s Disease.